key: cord-0865413-pmolz72n
authors: Wan, Jinkai; Xing, Shenghui; Ding, Longfei; Wang, Yongheng; Zhu, Dandan; Rong, Bowen; Wang, Siqing; Chen, Kun; He, Chenxi; Yuan, Songhua; Qiu, Chengli; Zhao, Chen; Zhang, Xiaoyan; Wang, Xiangxi; Lu, Yanan; Xu, Jianqing; Lan, Fei
title: Human IgG neutralizing monoclonal antibodies block SARS-CoV-2 infection
date: 2020-05-28
journal: bioRxiv
DOI: 10.1101/2020.05.19.104117
sha: eea4b903194dfa9e7be1fce1dff8cf94c97e40d2
doc_id: 865413
cord_uid: pmolz72n

The coronavirus induced disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a worldwide threat to human lives, and neutralizing antibodies present a great therapeutic potential in curing affected patients. We purified more than one thousand memory B cells specific to SARS-CoV-2 S1 or RBD (receptor binding domain) antigens from 11 convalescent COVID-19 patients, and a total of 729 naturally paired heavy and light chain fragments were obtained by single B cell cloning technology. Among these, 178 recombinant monoclonal antibodies were tested positive for antigen binding, and the top 13 binders with Kd below 0.5 nM are all RBD binders. Importantly, all these 13 antibodies could block pseudoviral entry into HEK293T cells overexpressing ACE2, with the best ones showing IC50s around 2-3 nM. We further identified 8 neutralizing antibodies against authentic virus with IC50s within 10 nM. Among these, 414-1 blocked authentic viral entry at IC50 of 1.75 nM and in combination with 105-38 could achieve IC50 as low as 0.45 nM. Meanwhile, we also found that 3 antibodies could cross-react with the SARS-CoV spike protein. Altogether, our study provided a panel of potent human neutralizing antibodies for COVID19 as therapeutics candidates for further development.

Over the last two decades in 21th century, the outbreaks of several viral infectious diseases affected millions of people 1-7 . Among these, 3 coronaviruses, SARS-CoV, MERS and SARS-CoV-2 8 , have received significant attention especially due to current outbreak of COVID-19 caused by SARS-CoV-2, and high mortality rates of the infected individuals. Most patients died due to severe pneumonia and multi-organ Owing to recent rapid development of single cell cloning technology, the process of antibody identification has been much shortened, from years to even less than 1 month. Therefore, full human and humanized neutralizing antibodies represent as great hopes for a prompt development of therapeutics in treating infectious diseases.

In support of this, cocktail treatment of 3 mixed antibodies recognizing different epitopes, with one of them able to robustly neutralize, was successfully used in the curation of a British Ebola patient 12, 13 . Regarding coronaviruses, neutralizing antibodies against MERS were tested effective in animals 14 . While SARS-CoV neutralizing antibodies did not meet human due to lack of patients after the development. Interestingly one of them, S309, was shown to be able to cross-react with and neutralize SARS-CoV-2 15 . However, the RBD regions (key targets for viral neutralization, also see below) only share 74% sequence identity between the two SARS viruses 16 , raising concerns about the effectiveness of SARS-CoV neutralizing antibodies against SARS-CoV-2.

The spike proteins of coronaviruses play an essential role in viral entry into human target cells. The S1 region, especially the RBD domain, primes the viral particle to human cell surface through the interaction with the receptor protein Angiotensin I Converting Enzyme 2 (ACE2) 17 , which then triggers infusion process primarily mediated by S2 region 18 . The primary amino acid sequences of the spike proteins of SARS-CoV and SARS-CoV-2 share 76 % identity throughout the full coding regions, with 79.59 % similarity and 74% identity in RBD domains 16, 19, 20 . Structure analyses revealed high 3D similarity between the spike proteins of the two viruses, and both trimerize and interact with ACE2 through the RBD domains 21 . Importantly, the interaction between the SARS-CoV-2 RBD and ACE2 was assessed at around 1.2 nM 18, 22 , 4 folds stronger than the SARS-CoV RBD. While this enhanced affinity may explain a much stronger spreading ability of SARS-CoV-2, it also suggests that finding potent neutralizing antibodies targeting SARS-CoV-2 RBD could also be more challenging.

While this manuscript was under preparation, identification of multiple human neutralizing monoclonal antibodies had been reported by a few studies [23] [24] [25] [26] [27] . While these groups and ours all employed similar approaches and obtained authentic viral neutralizing antibodies, the performances of these antibodies varied largely in different assays, e.g. the correlation between binding affinities, pseudoviral and authentic viral neutralizing abilities. Nevertheless, more human antibodies either directly neutralizing SARS-CoV-2 or opsonizing free viral particles for rapid immune clearances are still needed.

Here, we report the identification of 178 S1 and RBD binding full human monoclonal antibodies from the memory B cells of 11 recently recovered patients. The CDR3 sequences of the vast majority of these antibodies are different, indicating they are developed from different B cell clones. A total of 13 antibodies showed binding affinities lower than 0.5 nM and pseudoviral neutralizing abilities. We further identified 8 antibodies showing robust authentic viral neutralizing capabilities. Among these, the best one, 414-1, showed authentic viral neutralization IC50 at 1.75 nM. Moreover, we also identified 3 antibodies cross-reacting with SARS-CoV spike protein.

We screened 11 patients recently recovered from COVID-19, and identified 9 out of 11 individuals with strong serological responses to SARS-CoV-2 Spike RBD and S1 protein ( Figure 1 A and 1B) , and 7 sera showed neutralization abilities for SARS-CoV-2 pseudoviral infection of HEK293T cells stably expressing human ACE2 ( Figure 1B ). Therefore, sera from different individuals displayed a wide range of antibody responses to SARS-CoV-2 infection in our assays, consistent with a recent report 28 .

The RBD domain in the S1 region of SARS-CoV-2 spike protein is the critical region mediating viral entry through host receptor ACE2. Using recombinant viral antigens, we then isolated RBD and S1 binding memory B cells for antibody identification using the PBMCs (peripheral blood mononuclear cells) from 11 individuals by flow cytometry-based sorting technology ( Figure 1A) . Each individual exhibited different frequencies of viral antigen specific memory B cells ( Figure S1 and Table S1 ).

Sequences encoding antibody heavy (IGH) and light (IGL) chains were amplified from single B cell complementary DNA samples after reverse transcription and then cloned through homologous recombination into mammalian expressing vectors 29 . Overall, 729 naturally paired antibody genes were obtained from the 11 individuals, of which the No.71 individual failed to give any positive antibody. However, no strong correlation was found between serological responses and the number of acquired SARS-CoV-2 S-specific antibodies ( Figure 1B and Table S1 ), while we could not rule out possibilities of certain technical variations being involved. Of note, No.509 blood sample was obtained at the second day after hospitalization (Table S2) , the sera already showed weak S-specific affinity and pseudoviral neutralizing capacity, despite that no strong antibodies were obtained from No.509 sample.

All the 729 antibodies were further expressed in HEK293E cells and the supernatants were tested in ELISA for S1 or RBD binding (Figure 2A and Figure S2 ). Among these, 178 antibody supernatants were positive for RBD or S1 binding. We then purified all these antibodies in larger quantities to measure the precise values of Kd (EC50), and found the values varied broadly, with the most potent one at 57 pM (8.55 pg/µl), and 13 strongest ones having Kd below 0.5 nM ( Figure 2B ). All the positive clones were then sequenced. Notably, almost all (98.6%) of the sequences obtained were unique ones ( Figure 2C, left) , unlike what were previously reported for HIV-1, influenza and ZIKV 29 . Subsequently, we aligned the CDR3 of heavy chain (CDR3H) sequences of all these 13 antibodies and found 11 sequences are different, with the exceptions of 515-1 and 505-5 ( Figure 2C , right). Interestingly, 515-1 and 505-5 also shared the same CDR3L sequences, and they indeed behaved very similarly in the subsequent tests (see below).

As the spike S1 protein of SARS-CoV-2 tends to undergo conformation changes during storage, we also performed flow cytometry analyses for all 729 purified antibodies or supernatants for the binding ability of the freshly expressed spike protein in the membrane bound form using HEK293T cells ( Figure 2D ). Among these 729 antibodies, 58 were obtained from B cells purified by recombinant RBD domain, and 671 were from B cells purified by recombinant S1 protein. 

To identify neutralizing antibodies, we first employed pseudoviral infection assays using HEK293T-ACE2 cells. From all the antibodies tested, we found a total of 15 pseudoviral neutralizing antibodies. The best 3 antibodies in neutralizing pseudoviruses are 414-1, 505-3 and 553-63 ( Figure 3 A and 3B, IC50 from 2.3 to 3.6 nM), all of which showed strong affinities towards RBD domain ( Figure 3A and 3B, Kd from 0.079 nM to 0.31 nM) and could also robustly block RBD and ACE2 binding using ELISA ( Figure 3C ), indicating certain level of correlation between these abilities.

To our surprise, two of the 15 pseudoviral neutralizing antibodies, 413-2 and 505-8, only bound RBD very weakly in ELISA (Table S3 ), but were able to strongly recognize membrane-S protein overexpressing in HEK293T cells (Table S3) , indicating there is an alternative neutralization mechanism of non-RBD binders.

Among the 15 pseudoviral neutralization antibodies, all could bind S protein expressed in cell membrane detected by flow cytometry analyses. To further validate these antibodies, we employed two ACE2 competition assays. One assay was to test the ability in blocking ACE2 and RBD binding using ELISA, and the second assay was to compete free ACE2 binding to S protein expressing in A549 membrane using flow cytometry ( Figure 3C and Table S3 ). In order to perform the latter assay, we first tested various concentrations of soluble PE-labeled ACE2 in labeling 10 thousands of A549 overexpressing S protein, and found 50 nM ACE2 could label the vast majority of the cells ( Figure S3 ). Then, we used 0.1, 1 and 10 nM antibodies to compete 50 nM ACE2 for the binding of S on A549 membrane. All 15 pseudoviral neutralizing antibodies, except for 553-20, could compete ACE2 ( Figure S4A ). However, the competition abilities did not show significant correlation with neutralizing abilities. For instances, 414-1 and 553-63 are the strongest neutralizing antibodies, however, 0.1 nM 553-63 could reach 50% competition against 50 nM ACE2 while 414-1 needed 10 nM ( Figure 3C and Figure S4B ).

We then performed authentic viral neutralization assay for the best 11 antibodies using Vero-E6 ( Figure 3A ), and found a total of 8 antibodies showing IC50 at for below 10 nM. The best one, 414-1, was able to effectively block authentic viral entry at IC50 of 1.75 nM, and when combined with 105-38 the IC50 could further reduced to 0.45 nM ( Figure 3D ). To note, although 105-38 showed a much weaker neutralizing ability by itself in pseudoviral assay, but it recognized different epitope as 414-1 (data not shown), explaining the combinatorial enhancement. We also tested 414-1 expressing in CHO cells, and found it could achieve ~ 300 mg/L without any optimization suggesting for great potential in therapeutic development. Subsequently, 414-1 was also tested in pH 5.0 for affinity maintenance by ELISA ( Figure 3D ), the results (Kd= 0.31 nM in pH7.4 and Kd= 0.56 nM in pH5.0) showed a good affinity performance in low pH, indicating less probability in causing ADE. Furthermore, 414-1 was also tested by BLI, and showed comparable Kd ( Figure 3D ).

The spike proteins of SARS-CoV-2 share 76% and 35% of amino acid identities with SARS-CoV and MERS-CoV, respectively. Therefore, we next tested whether our antibodies could cross-react with the S proteins of these two other coronaviruses. In order to do so, we overexpressed the S proteins of SARS-CoV-2, SARS-CoV and MERS-CoV in HEK293T, and tested the cross-reactivities by flow cytometry analyses.

After removal of the antibodies showing non-specific binding to HEK293T cells, we focused on 30 antibodies with robust membrane SARS-CoV-2 S protein binding abilities ( Figure 4A ), among them, we found 3 antibodies, 415-5, 415-6 and 515-5, recognizing SARS-CoV S, but none could recognize MERS-CoV S ( Figure 4B ). 415-5 and 515-5 shared similar S protein affinities between SARS-CoV-2 and SARS-CoV, but 415-6 had much lower affinity towards SARS-CoV S ( Figure 4C ).

Within last few weeks, several groups had published a panel of full human neutralizing antibodies against COVID19 [23] [24] [25] [26] [27] 30 . To date, a total of 28 human antibodies had been reported to show neutralizing abilities against authentic SARS-CoV-2, and here we added 11 more to the reservoir. Among these, 20

reported ones showed neutralizing IC50 within 10 nM, a general potency guideline for potential clinical use, and here we reported 8 new ones.

In our study, in order to provide good therapeutic candidates of monoclonal antibodies, we have implemented multiple approaches during the triage processes before authentic viral testing. Our triage approaches included, 1) RBD and S binding abilities by ELISA; 2) membrane S binding abilities by flow cytometry; 3) ACE2 competition abilities using both ELISA and flow cytometry; 4) pseudoviral neutralization assay. The best 3 antibodies, 414-1, 505-3 and 553-63, showed consistent performances in all these assays (Table S3 ). The other 5 antibodies with IC50 within 10nM for authentic viral neutralization also showed relatively consistent performances in most of the assays (Table S3 ). In general, the 7 of the top 8 neutralizing antibodies showed robust binding abilities in the ELISA assays. The only one exception is 505-8, however, it functioned well in flow cytometry-based binding and competition assays (Table S3 , column 6-7, also see below), indicating that binding affinity is a fundamental quality for neutralizing capacity in our study. And we observed a general increase of neutralizing IC50 values compared to binding affinity EC50 values. However, compared with other studies mentioned above, we found that the leading antibodies reported in the studies by Cao et al 23 Among the top 30 antibodies, 24 were obtained from B cells isolated using S1 protein.

We found the majority, 18 of 24, are RBD binders, and two of them, 413-2 and 553-13, are strong S binders but not RBD binders tested by ELISA (Table S3 , last two columns). These findings indicated that the RBD region is the primary epitope for immune responses. Similar observations were also reported elsewhere for SARS-CoV-2 23,27 as well as SARS-CoV 31,32 . We also found another 4 antibodies, 505-8, 505-17, 515-5 and 553-18, showed barely any ELISA signals towards both RBD and S, but could robustly bind freshly expressed S protein in A549 membrane (Table S3 ). These included one neutralizing antibody 505-8 mentioned above, indicating that the recombinant RBD or S protein may differ from the membrane bound S in terms of 3D conformation. We would have missed these antibodies if we only had used ELISA for antibody triage. Therefore, future antibody study should consider multiple approaches for the initial identification and quality control. 

Fei Lan is a scientific advisor of Active Motif China Inc.

The experiments involving authentic COVID-19 virus were performed in Fudan University biosafety level 3 (BSL-3) facility. The overall study was reviewed and approved by the SHAPHC Ethics Committee (approval no. 2020-Y008-01).

Vero E6, A549-Spike (A549 expressing SARS-CoV-2 S protein), and A549-ACE2 The fluorescently labeled S1 bait was previously prepared by incubating 5 μg of His tag-S1 protein with Anti His tag antibody-PE for at least 1 hr at 4 ℃ in the dark. 

Interferometry. RBD diluted in a 2-fold series by assay buffer (20mM MOPs, 50 nM KCl, pH 7.4).

For Figure Flow cytometry analysis was also performed to detect the ACE2 competition ( Figure   3C and Table S3 ). Then 10 thousand S expressing cells in 100 µl were first incubated with free ACE2 at 50nM for 30 min at room temperature, then different concentrations of antibodies were added for 30 min, followed by incubation with PE-labeled goat anti-human IgG-Fc antibody (1:5000; Abcam) for 30 min and analyzed by flow cytometry.

For Figure S3 , to test S protein expression on cell membrane, recombinant ACE2-Cter-6XHis labeled by rabbit anti-His-PE antibody in 1.2:1(n:n) ratio was added to 10 thousand cells expressing S protein. Detection was done similarly as above.

Coding 71  192  16  105  192  42  413  192  35  414  192  38  415  192  22  501  192  87  505  192  74  509  192  36  507  384  146  515  192  81  553  384  152  Total 2304 729 

Role of the Ebola membrane in the protection conferred by the three-mAb cocktail MIL77

A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection

Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerging Microbes & Infections 9

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

A potent neutralizing human antibody reveals the N-terminal domain of the Spike protein of SARS-CoV-2 as a site of vulnerability. bioRxiv

A human monoclonal antibody blocking SARS-CoV-2 infection

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. medRxiv

We appreciate the Novoprotein Scientific Inc. for gifting SARS-CoV-2 Spike, ACE2 Table.S2